Reversal of Fragile X Phenotypes by Manipulation of AβPP/Aβ Levels in Fmr1KO Mice

Fragile X syndrome (FXS) is the most common form of inherited intellectual disability and the leading known genetic cause of autism. Fragile X mental retardation protein (FMRP), which is absent or expressed at substantially reduced levels in FXS, binds to and controls the postsynaptic translation of amyloid β-protein precursor (AβPP) mRNA. Cleavage of AβPP can produce β-amyloid (Aβ), a 39–43 amino acid peptide mis-expressed in Alzheimer's disease (AD) and Down syndrome (DS). Aβ is over-expressed in the brain of Fmr1KO mice, suggesting a pathogenic role in FXS. To determine if genetic reduction of AβPP/Aβ rescues characteristic FXS phenotypes, we assessed audiogenic seizures (AGS), anxiety, the ratio of mature versus immature dendritic spines and metabotropic glutamate receptor (mGluR)-mediated long-term depression (LTD) in Fmr1KO mice after removal of one App allele. All of these phenotypes were partially or completely reverted to normal. Plasma Aβ1–42 was significantly reduced in full-mutation FXS males compared to age-matched controls while cortical and hippocampal levels were somewhat increased, suggesting that Aβ is sequestered in the brain. Evolving therapies directed at reducing Aβ in AD may be applicable to FXS and Aβ may serve as a plasma-based biomarker to facilitate disease diagnosis or assess therapeutic efficacy.

[1]  W. Klein,et al.  Deleterious Effects of Amyloid β Oligomers Acting as an Extracellular Scaffold for mGluR5 , 2010, Neuron.

[2]  E. F. da Cruz e Silva,et al.  Aβ promotes Alzheimer’s disease‐like cytoskeleton abnormalities with consequences to APP processing in neurons , 2010, Journal of neurochemistry.

[3]  P. Scheltens,et al.  Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment , 2010, Neurobiology of Aging.

[4]  Anders Wallin,et al.  Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment , 2010, Neurobiology of Aging.

[5]  J. Malter,et al.  Alzheimer's disease and Down syndrome rodent models exhibit audiogenic seizures. , 2010, Journal of Alzheimer's disease : JAD.

[6]  J. Sweatt,et al.  NADPH oxidase mediates β-amyloid peptide-induced activation of ERK in hippocampal organotypic cultures , 2009, Molecular Brain.

[7]  Shaomin Li,et al.  Soluble Oligomers of Amyloid β Protein Facilitate Hippocampal Long-Term Depression by Disrupting Neuronal Glutamate Uptake , 2009, Neuron.

[8]  R. Paylor,et al.  Marble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety , 2009, Psychopharmacology.

[9]  J. Malter,et al.  Translating memories: The role of protein biosynthesis in synpatic plasticity , 2009 .

[10]  I. Weiler,et al.  Early‐phase ERK activation as a biomarker for metabolic status in fragile X syndrome , 2008, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[11]  Michelle N. Ngo,et al.  Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model , 2008, Journal of Medical Genetics.

[12]  H. Fukuyama,et al.  Peripheral Aβ subspecies as risk biomarkers of Alzheimer's disease , 2008, Proceedings of the National Academy of Sciences.

[13]  D. Geschwind,et al.  Biochemical markers in persons with preclinical familial Alzheimer disease , 2008, Neurology.

[14]  Chris I. De Zeeuw,et al.  Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice , 2008, Neurobiology of Disease.

[15]  M. Bear,et al.  Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome , 2008, The Journal of physiology.

[16]  C. Sanberg,et al.  Peripheral biomarkers in Autism: secreted amyloid precursor protein-alpha as a probable key player in early diagnosis. , 2008, International journal of clinical and experimental medicine.

[17]  Mark F. Bear,et al.  Correction of Fragile X Syndrome in Mice , 2007, Neuron.

[18]  R. Mayeux,et al.  Elevated plasma beta-amyloid peptide Abeta(42) levels, incident dementia, and mortality in Down syndrome. , 2007, Archives of neurology.

[19]  D. Loesch,et al.  Autism Spectrum Phenotype in Males and Females with Fragile X Full Mutation and Premutation , 2007, Journal of autism and developmental disorders.

[20]  R. Freedland,et al.  Increased amyloid β protein levels in children and adolescents with Down syndrome , 2007, Journal of the Neurological Sciences.

[21]  R. Petersen,et al.  Association of Low Plasma Aβ42/Aβ40 Ratios With Increased Imminent Risk for Mild Cognitive Impairment and Alzheimer Disease , 2007 .

[22]  J. Malter,et al.  FMRP Mediates mGluR5-Dependent Translation of Amyloid Precursor Protein , 2007, PLoS biology.

[23]  R. Petersen,et al.  Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. , 2007, Archives of neurology.

[24]  A. Hofman,et al.  Plasma Aβ1–40 and Aβ1–42 and the risk of dementia: a prospective case-cohort study , 2006, The Lancet Neurology.

[25]  M. Farlow,et al.  High Levels of Alzheimer Beta-Amyloid Precursor Protein (APP) in Children With Severely Autistic Behavior and Aggression , 2006, Journal of child neurology.

[26]  P. Spano,et al.  Regulation of Nuclear Factor κB in the Hippocampus by Group I Metabotropic Glutamate Receptors , 2006, The Journal of Neuroscience.

[27]  R. Carroll,et al.  Local functions for FMRP in axon growth cone motility and activity-dependent regulation of filopodia and spine synapses , 2006, Molecular and Cellular Neuroscience.

[28]  Karolina Nilsson,et al.  Phenyl ureas of creatinine as mGluR5 antagonists. A structure-activity relationship study of fenobam analogues. , 2006, Bioorganic & medicinal chemistry letters.

[29]  R. Veerhuis,et al.  Inhibitory effect of minocycline on amyloid β fibril formation and human microglial activation , 2006, Glia.

[30]  A. Hofman,et al.  Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. , 2006, The Lancet. Neurology.

[31]  C. Smith,et al.  A null mutation for Fmr1 in female mice: Effects on regional cerebral metabolic rate for glucose and relationship to behavior , 2005, Neuroscience.

[32]  M. Tranfaglia,et al.  Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP , 2005, Neuropharmacology.

[33]  P. Greengard,et al.  Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses , 2005, Neurobiology of Disease.

[34]  Jens-Uwe Peters,et al.  Fenobam: A Clinically Validated Nonbenzodiazepine Anxiolytic Is a Potent, Selective, and Noncompetitive mGlu5 Receptor Antagonist with Inverse Agonist Activity , 2005, Journal of Pharmacology and Experimental Therapeutics.

[35]  W. Greenough,et al.  From mRNP trafficking to spine dysmorphogenesis: the roots of fragile X syndrome , 2005, Nature Reviews Neuroscience.

[36]  Yan Wang,et al.  Pharmacological Rescue of Synaptic Plasticity, Courtship Behavior, and Mushroom Body Defects in a Drosophila Model of Fragile X Syndrome , 2005, Neuron.

[37]  I. Kloszewska,et al.  Plasma levels of alpha beta peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer's disease. , 2005, Acta neurobiologiae experimentalis.

[38]  R. E. Brown,et al.  A phenotypic and molecular characterization of the fmr1‐tm1Cgr Fragile X mouse , 2004, Genes, brain, and behavior.

[39]  C. Finch,et al.  Synaptic Targeting by Alzheimer's-Related Amyloid β Oligomers , 2004, The Journal of Neuroscience.

[40]  S. Warren,et al.  The fragile X protein controls microtubule-associated protein 1B translation and microtubule stability in brain neuron development. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[41]  J. Sweatt,et al.  MAPK recruitment by β‐amyloid in organotypic hippocampal slice cultures depends on physical state and exposure time , 2004, Journal of neurochemistry.

[42]  Prasongchai Sattayaprasert,et al.  Minocycline inhibits neuronal death and glial activation induced by β‐amyloid peptide in rat hippocampus , 2004, Glia.

[43]  M. Inglese,et al.  Plasma levels of amyloid β-protein 42 are increased in women with mild cognitive impairment , 2004, Neurology.

[44]  Mark F Bear,et al.  The mGluR theory of fragile X mental retardation , 2004, Trends in Neurosciences.

[45]  Alcino J. Silva,et al.  Sensorimotor gating abnormalities in young males with fragile X syndrome and Fmr1-knockout mice , 2004, Molecular Psychiatry.

[46]  R. Anwyl,et al.  Block of Long-Term Potentiation by Naturally Secreted and Synthetic Amyloid β-Peptide in Hippocampal Slices Is Mediated via Activation of the Kinases c-Jun N-Terminal Kinase, Cyclin-Dependent Kinase 5, and p38 Mitogen-Activated Protein Kinase as well as Metabotropic Glutamate Receptor Type 5 , 2004, The Journal of Neuroscience.

[47]  C. Finch,et al.  Synaptic targeting by Alzheimer's-related amyloid beta oligomers. , 2004, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[48]  R. Mayeux,et al.  Plasma A&bgr;40 and A&bgr;42 and Alzheimer’s disease: Relation to age, mortality, and risk , 2003 .

[49]  R. Malinow,et al.  APP Processing and Synaptic Function , 2003, Neuron.

[50]  B. Oostra,et al.  The Fragile X Syndrome Protein FMRP Associates with BC1 RNA and Regulates the Translation of Specific mRNAs at Synapses , 2003, Cell.

[51]  I. Weiler,et al.  RNA Cargoes Associating with FMRP Reveal Deficits in Cellular Functioning in Fmr1 Null Mice , 2003, Neuron.

[52]  L S Honig,et al.  Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. , 2003, Neurology.

[53]  Lorenzo Pavone,et al.  Epilepsy in fragile X syndrome , 2002, Brain and Development.

[54]  É. Khandjian,et al.  Trapping of messenger RNA by Fragile X Mental Retardation protein into cytoplasmic granules induces translation repression. , 2002, Human molecular genetics.

[55]  D. Alkon,et al.  Gene Expression Profiles in a Transgenic Animal Model of Fragile X Syndrome , 2002, Neurobiology of Disease.

[56]  Mark F. Bear,et al.  Altered synaptic plasticity in a mouse model of fragile X mental retardation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[57]  V. Ingram,et al.  Mechanism of membrane depolarization caused by the Alzheimer Abeta1-42 peptide. , 2002, Biochemical and biophysical research communications.

[58]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[59]  Brett Chromy,et al.  Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus , 2002, Brain Research.

[60]  W Blaine Stine,et al.  Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. , 2002, Brain research.

[61]  J. Darnell,et al.  Microarray Identification of FMRP-Associated Brain mRNAs and Altered mRNA Translational Profiles in Fragile X Syndrome , 2001, Cell.

[62]  J. Malter,et al.  Extracellular-regulated kinase controls β-amyloid precursor protein mRNA decay , 2001 .

[63]  S. Warren,et al.  The fragile X mental retardation protein inhibits translation via interacting with mRNA. , 2001, Nucleic acids research.

[64]  L. Chen,et al.  Fragile X mice develop sensory hyperreactivity to auditory stimuli , 2001, Neuroscience.

[65]  A. Ostareck-Lederer,et al.  Evidence that fragile X mental retardation protein is a negative regulator of translation. , 2001, Human molecular genetics.

[66]  I. Weiler,et al.  Abnormal dendritic spine characteristics in the temporal and visual cortices of patients with fragile-X syndrome: a quantitative examination. , 2001, American journal of medical genetics.

[67]  J. Malter,et al.  Extracellular-regulated kinase controls beta-amyloid precursor protein mRNA decay. , 2001, Brain research. Molecular brain research.

[68]  M. Bear,et al.  Role for rapid dendritic protein synthesis in hippocampal mGluR-dependent long-term depression. , 2000, Science.

[69]  Nicoletta Berardi,et al.  Critical periods during sensory development , 2000, Current Opinion in Neurobiology.

[70]  H. Moser,et al.  Dendritic anomalies in disorders associated with mental retardation. , 1999, Cerebral cortex.

[71]  H. Wiśniewski,et al.  Plasma and cerebrospinal fluid Levels of amyloid β proteins 1-40 and 1-42 in Alzheimer disease , 2000 .

[72]  V. Budnik,et al.  The Drosophila β-Amyloid Precursor Protein Homolog Promotes Synapse Differentiation at the Neuromuscular Junction , 1999, The Journal of Neuroscience.

[73]  P. Bosco,et al.  Epilepsy and EEG Findings in Males with Fragile X Syndrome , 1999, Epilepsia.

[74]  R. Hagerman,et al.  Fragile X syndrome and selective mutism. , 1999, American journal of medical genetics.

[75]  D. McIntosh,et al.  Electrodermal responses to sensory stimuli in individuals with fragile X syndrome: a preliminary report. , 1999, American journal of medical genetics.

[76]  L. Kent,et al.  Comorbidity of autistic spectrum disorders in children with Down syndrome , 1999, Developmental medicine and child neurology.

[77]  T. Morgan,et al.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[78]  A. Taylor,et al.  Molecular-clinical correlations in males with an expanded FMR1 mutation. , 1996, American journal of medical genetics.

[79]  M. Ball,et al.  Water-soluble A(N-40, N-42) Oligomers in Normal and Alzheimer Disease Brains (*) , 1996, The Journal of Biological Chemistry.

[80]  S. Appel,et al.  β‐Amyloid1–40 Increases Expression of β‐Amyloid Precursor Protein in Neuronal Hybrid Cells , 1995 .

[81]  G. Dawson,et al.  β-amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity , 1995, Cell.

[82]  S. Appel,et al.  beta-Amyloid1-40 increases expression of beta-amyloid precursor protein in neuronal hybrid cells. , 1995, Journal of Neurochemistry.

[83]  L. Mucke,et al.  Synaptotrophic effects of human amyloid β protein precursors in the cortex of transgenic mice , 1994, Brain Research.

[84]  Guy Nagels,et al.  Fmr1 knockout mice: A model to study fragile X mental retardation , 1994, Cell.

[85]  G. Schneider,et al.  The amyloid precursor protein is developmentally regulated and correlated with synaptogenesis. , 1994, Developmental biology.

[86]  C. Masters,et al.  Regulation and Expression of the Alzheimer's β/A4 Amyloid Protein Precursor in Health, Disease, and Down's Syndrome a , 1993, Annals of the New York Academy of Sciences.

[87]  E. Berry-Kravis,et al.  Demonstration of abnormal cyclic AMP production in platelets from patients with fragile X syndrome. , 1993, American journal of medical genetics.

[88]  E. Masliah,et al.  Amyloid precursor protein is localized in growing neurites of neonatal rat brain , 1992, Brain Research.

[89]  D. Selkoe,et al.  Increased expression of beta-amyloid precursor protein during neuronal differentiation is not accompanied by secretory cleavage. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[90]  G. Huber,et al.  β‐Amyloid Precursor Protein Isoforms in Various Rat Brain Regions and During Brain Development , 1992 .

[91]  G. Huber,et al.  Beta-amyloid precursor protein isoforms in various rat brain regions and during brain development. , 1992, Journal of neurochemistry.

[92]  W. Brown,et al.  Analysis of neocortex in three males with the fragile X syndrome. , 1991, American journal of medical genetics.

[93]  J. Sutcliffe,et al.  Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome , 1991, Cell.

[94]  J. Mandel,et al.  Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome , 1991, Science.

[95]  K. Wisniewski,et al.  The Fra(X) syndrome: neurological, electrophysiological, and neuropathological abnormalities. , 1991, American journal of medical genetics.

[96]  C. Masters,et al.  Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[97]  H. Wiśniewski,et al.  Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome , 1985, Annals of neurology.

[98]  M. Reivich,et al.  ACTIVATION , 1980, The Social Value of Zoos.